MIRA Pharmaceuticals

?? $MIRA MIRA Pharmaceuticals Announces Key Milestone in Ketamir-2 Clinical Development! We're thrilled to share an exciting update as MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) accelerates its journey toward becoming a clinical-stage company! ?? Clinical Trial Site Selected: We've chosen The Centre for Human Drug Research (CHDR) in Leiden, The Netherlands, as the site for our Phase I/IIa trial for Ketamir-2, our novel oral ketamine analog. Recruitment begins in Q1 2025, and initial safety and efficacy data is expected in the second half of 2025. ?? Why CHDR? Their cutting-edge PainCart? technology will allow us to assess early signs of Ketamir-2’s efficacy in healthy subjects during Phase I—a groundbreaking approach to pain management. ?? Innovative Study Design: Our trial will include: Phase I: Focused on safety, tolerability, and early efficacy in healthy subjects. Phase IIa: Targeting diabetic neuropathy patients, with initial efficacy data anticipated in the first half of 2026. ?? Advancing Breakthroughs: Ketamir-2 has shown superior efficacy compared to existing drugs like pregabalin and gabapentin, offering a potential non-addictive, safe, and effective solution for pain and depression. ?? Strong Financial Position: With a healthy balance sheet, MIRA is well-equipped to achieve these milestones without unfavorable financing deals. ?? Looking Ahead: As we transition into a clinical-stage company, we remain dedicated to building strategic partnerships, advancing Ketamir-2, and exploring its potential across additional indications. ?? Visit our website to learn more: https://lnkd.in/eZNZzHR7 Together, we're redefining possibilities in pain and depression treatment. ?? #Pharmaceuticals #ClinicalTrials #Innovation #PainManagement #DepressionTreatment #Biotech #FDA

?? $MIRA Exciting update on MIRA Pharmaceuticals! The recent Zacks Investment Research report recognizes our strong financial positioning and effective management, highlighting our solid balance sheet and limited liabilities—key strengths for a preclinical company. This financial foundation empowers us to continue advancing innovative treatments like Ketamir-2 for neuropathic pain, Depression and PTSD, while we pursue non-dilutive funding and partnerships opportunities. #Mira #NeuropathicPain #ClinicalTrials #PTSD #Depression #FDA #DrugDiscovery Read the full report for insights into our financial health and growth potential: https://lnkd.in/dX59-YKp

?? $MIRA Updated Analyst Report on MIRA Pharmaceuticals! Kingswood U.S. has released an updated report on MIRA Pharmaceuticals (Nasdaq: MIRA), reaffirming a BUY rating with a target price of $7.50. The report highlights our continued progress with Ketamir-2 for pain management and MIRA-55 for cognitive health. Read the full report for the latest insights. #biotech #pharmaceuticals #MIRA #pain #FDA #humantrials

$MIRA Exciting News from the Pain Therapeutics Summit! We are thrilled to share the successful presentation of our latest preclinical data on Ketamir-2 at the Pain Therapeutics Summit. Our poster, titled “Selective NMDA Receptor Modulation: The Superior Efficacy of Ketamir-2 in Neuropathic Pain Treatment”, garnered an incredible response from the scientific community, highlighting the potential of Ketamir-2 in transforming neuropathic pain management. ?? Key Takeaways: ? Superior Pain Relief: Ketamir-2 demonstrated significant pain reduction in preclinical models, achieving complete pain normalization at higher doses. ? Broad Efficacy: Outperformed ketamine, pregabalin, and gabapentin in both nerve injury and chemotherapy-induced neuropathy models. ? Safer Profile: Targeted NMDA receptor modulation minimizes side effects, with improved bioavailability, offering a safer treatment option. A huge thank you to everyone who visited our poster and engaged in discussions. We’re excited to continue advancing Ketamir-2, bringing us one step closer to redefining pain management for patients in need. Stay tuned for more updates! #PainTherapeuticsSummit #Ketamir2 #NeuropathicPain #MiraPharmaceuticals #InnovationInPainManagement #ClinicalResearch

$MIRA Exciting advancements at MIRA Pharmaceuticals! Our novel drug, Ketamir-2, has shown 60% greater efficacy than FDA-approved gabapentin in preclinical studies for treating chemotherapy-induced neuropathic pain. This breakthrough offers hope for a safer, non-opioid solution for patients battling severe pain. We’ll be presenting these findings at the Pain Therapeutics Summit in Boston, sharing our commitment to improving neuropathic pain treatment. With potential FDA designations like breakthrough therapy on the horizon, we’re accelerating our efforts to bring Ketamir-2 to those who need it most. Stay tuned as we move closer to clinical trials in 2025. Proud to be part of this journey toward transformative pain management. https://lnkd.in/e2arjPMq #MIRAPharmaceuticals #Ketamir2 #PainManagement #Innovation #Biotech #NeuropathicPain #BostonSummit

MIRA Pharmaceuticals KETAMIR-2 shines in preclinical studies, outperforming existing pain treatments with improved safety! ?? A promising leap in inflammation and pain management therapy. Know complete story - https://lnkd.in/djh6GaWV #KETAMIR2 #PainManagement #InnovativeTherapy #PharmaBreakthrough

Breakthrough Preclinical Results: MIRA Pharmaceuticals $MIRA Ketamir-2 Surpasses Leading Neuropathic Pain Treatments #stockstowatch #stocksinnews #investors #daytrader #PrismMarketView #PrismMediaWire #PrismDigitalMedia https://lnkd.in/e2QEiMVm

??$MIRA MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study ?? We are excited to share that our novel oral ketamine analog, Ketamir-2, has shown encouraging results in a recent preclinical study. The data demonstrated that Ketamir-2 provided up to 112% more effective pain relief than Pregabalin and 70% greater relief than Gabapentin at higher doses. Based on these new findings, we are very optimistic about Ketamir-2's potential to make a meaningful impact in pain management and beyond. Stay tuned for more updates as we advance this innovative therapy. ?? #biotech #neuropathicpain #pharmaceuticals #clinicaltrials #Ketamir2 #PTSD #innovation #MiraPharma #NASDAQ #MIRA #FDA https://lnkd.in/epHCuPrz

Small ?? Changes… Big Effects! ?? Breakthrough Therapies ?? Are The Name Of The Game For This Biopharma.???? MIRA Pharmaceuticals (NASDAQ: $MIRA) is developing novel treatments?? for neurologic ??and neuropsychiatric disorders. ?? https://lnkd.in/ew5DYPJ6 ?? #pharma #innovation #ad

?? $MIRA Exciting News for Mira Pharmaceuticals! ?? We're excited to share that Elemer Piros, PhD, from Rodman & Renshaw has initiated coverage of MIRA Pharmaceuticals with a Buy rating and a 12-month price target of $17 per share! Key catalysts from the report: ?? Advancing Toward Clinical Trials: Our innovative drug candidates—Ketamir-2 (a next-gen, orally bioavailable ketamine analog) and MIRA-55 (a breakthrough cannabis analog)—are progressing rapidly, with Ketamir-2 set to enter the clinic for neuropathic pain in early 2025. ?? Ketamir-2 is an unscheduled drug with significant potential as an oral, non-opioid pain management solution, addressing the critical need for alternatives to opioids in light of the ongoing opioid crisis. It's positioned to deliver at-home relief with its superior bioavailability. ?? MIRA-55, our second candidate, is a novel chemical entity that combines the therapeutic effects of THC and CBD without the side effects, targeting anxiety and cognitive enhancement. An IND filing for MIRA-55 is planned by year-end 2025, marking another significant milestone on the horizon. ?? With the opioid crisis costing the U.S. economy over $1 trillion annually, Mira is committed to offering safe, effective, and innovative non-opioid therapies. Our valuation is driven by the potential future cash flows from Ketamir-2 and beyond, with analysts estimating a $425M NPV through 2044. This is just the beginning—our pipeline is filled with promise, and we’re dedicated to transforming the landscape of pain and psychiatric treatments. Stay tuned for more updates as we push forward in this critical mission. #Biotech #Pharma #Innovation #Opioidcrisis #Clinicaltrials #Painmanagement #Mentalhealth #MIRA #Ketamir2 #MIRA55 #neuropathicPain #Depression #PTSD #FDA